Amina Zoubeidi
Amina Zoubeidi
University of British Columbia
Verified email at - Homepage
Cited by
Cited by
Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity
A Zoubeidi, A Zardan, E Beraldi, L Fazli, R Sowery, P Rennie, C Nelson, ...
Cancer research 67 (21), 10455-10465, 2007
Genomic hallmarks and structural variation in metastatic prostate cancer
DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ...
Cell 174 (3), 758-769. e9, 2018
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
JL Bishop, A Sio, A Angeles, ME Roberts, AA Azad, KN Chi, A Zoubeidi
Oncotarget 6 (1), 234, 2015
Small heat shock proteins in cancer therapy and prognosis
A Zoubeidi, M Gleave
The international journal of biochemistry & cell biology 44 (10), 1646-1656, 2012
Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer
M Shiota, JL Bishop, KM Nip, A Zardan, A Takeuchi, T Cordonnier, ...
Cancer research 73 (10), 3109-3119, 2013
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer
AV Lapuk, C Wu, AW Wyatt, A McPherson, BJ McConeghy, S Brahmbhatt, ...
The Journal of pathology 227 (3), 286-297, 2012
The placental gene PEG10 promotes progression of neuroendocrine prostate cancer
S Akamatsu, AW Wyatt, D Lin, S Lysakowski, F Zhang, S Kim, C Tse, ...
Cell reports 12 (6), 922-936, 2015
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer
A Zoubeidi, K Chi, M Gleave
Clinical Cancer Research 16 (4), 1088-1093, 2010
The master neural transcription factor BRN2 is an androgen receptor–suppressed driver of neuroendocrine differentiation in prostate cancer
JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ...
Cancer discovery 7 (1), 54-71, 2017
Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy
RD Sowery, BA Hadaschik, AI So, A Zoubeidi, L Fazli, A Hurtado‐Coll, ...
BJU international 102 (3), 389-397, 2008
Clusterin mediates TGF-β–induced epithelial–mesenchymal transition and metastasis via Twist1 in prostate cancer cells
M Shiota, A Zardan, A Takeuchi, M Kumano, E Beraldi, S Naito, ...
Cancer research 72 (20), 5261-5272, 2012
Clusterin facilitates COMMD1 and I-κB degradation to enhance NF-κB activity in prostate cancer cells
A Zoubeidi, S Ettinger, E Beraldi, B Hadaschik, A Zardan, LWJ Klomp, ...
Molecular Cancer Research 8 (1), 119-130, 2010
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
AH Davies, H Beltran, A Zoubeidi
Nature Reviews Urology 15 (5), 271-286, 2018
Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19
JT Hua, M Ahmed, H Guo, Y Zhang, S Chen, F Soares, J Lu, S Zhou, ...
Cell 174 (3), 564-575. e18, 2018
Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities
P Toren, A Zoubeidi
International journal of oncology 45 (5), 1793-1801, 2014
Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo
C Thomas, F Lamoureux, C Crafter, BR Davies, E Beraldi, L Fazli, S Kim, ...
Molecular cancer therapeutics 12 (11), 2342-2355, 2013
Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363
F Lamoureux, C Thomas, C Crafter, M Kumano, F Zhang, BR Davies, ...
Clinical cancer research 19 (4), 833-844, 2013
Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models
P Toren, S Kim, T Cordonnier, C Crafter, BR Davies, L Fazli, ME Gleave, ...
European urology 67 (6), 986-990, 2015
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer
F Lamoureux, C Thomas, MJ Yin, H Kuruma, E Beraldi, L Fazli, ...
Cancer research 71 (17), 5838-5849, 2011
Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth
Y Yamamoto, Y Loriot, E Beraldi, F Zhang, AW Wyatt, N Al Nakouzi, F Mo, ...
Clinical cancer research 21 (7), 1675-1687, 2015
The system can't perform the operation now. Try again later.
Articles 1–20